Risk of Depressive Episodes with Rimonabant
- First Online:
- 69 Downloads
Background: Marketing authorization for rimonabant was withdrawn in October 2008, mainly because the psychiatric adverse effects could not be addressed by further risk minimization.
Objective: The aim of the study was to compare the risk of major and minor depressive episodes in the 6 months prior to and the 6 months after starting treatment with rimonabant.
Methods: We conducted a before and after study using the observational cohort technique of Modified Prescription Event Monitoring to compare the risk of major and minor depressive episodes in new users of rimonabant reported in the 6 months before to the 6 months after starting treatment with rimonabant. Patients were identified from dispensed prescriptions issued by primary care physicians from June 2006 to October 2008. Patient demographics and information on depressive episodes were requested 6 months after the date of the first prescription for each patient. Risk ratios (RR) were calculated by comparing before and after events using a matched analysis.
Results: The cohort comprised 10011 patients. The number of patients who had major depressive episodes before and after starting treatment were 147 and 168, respectively (RR 1.14; 95% CI 0.94, 1.39) and the number of patients who had minor depressive episodes were 825 and 829, respectively (RR 1.00; 95% CI 0.93, 1.10). For patients who had a previous history of psychiatric illness (n= 1132), 91 and 73, respectively, experienced major depressive episodes (RR 0.80; 95% CI 0.62,1.03), and 367 and 220, respectively, experienced minor depressive episodes (RR 0.59; 95% CI 0.53, 0.68). For patients without a previous history of psychiatric illness (n = 8879), 56 and 95, respectively, experienced major depressive episodes (RR 1.7; 95% CI 1.2,2.3), and 458 and 609, respectively, experienced minor depressive episodes (RR 1.33; 95% CI 1.20, 1.48).
Conclusions: When comparing all patients in the cohort, there was no increased risk of developing a depressive episode whilst taking rimonabant. However, when considering subsets of patients with and without a previous history of psychiatric illness, the risk profiles were different. In patients without a previous history of psychiatric illness, there were more depressive episodes in the 6 months after starting treatment compared with the 6 months before starting treatment with rimonabant.
- 1.Sanofi-aventis. Acomplia: summary of product characteristics [online]. Available from URL: http://www.acompliareport.com/AcompliaSPC.htm [Accessed 2011 Feb 18]
- 5.World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: World Health Organization, 2000Google Scholar
- 19.European Medicines Agency. European Medicines Agency recommends Acomplia must not be used in patients on antidepressants or with major depression [media release]. 2007 Jul 19 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500012384.pdf [Accessed 2011 Apr 19]
- 20.European Medicines Agency. The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia [media release]. 2008 Oct 23 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500014774.pdf [Accessed 2011 Apr 19]
- 24.Shakir SAW. Prescription-event monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance. Chichester: John Wiley & Sons Ltd, 2007: 307–16Google Scholar
- 25.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Arlington (VA): American Psychiatric Association, 2005Google Scholar
- 26.CIOMS-WHO. International guidelines for biomedical research involving human subjects. Geneva: CIOMS-WHO, 2002Google Scholar
- 27.Greenland S. Applications of stratified analysis methods. In: Rothman K, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia (PA); Lippincott Williams and Wilkins, 2007: 281–99Google Scholar
- 28.Cummings P, McKnight B. Analysis of matched cohort data. Stata J 2006; 4(3): 274–81Google Scholar
- 29.Medicines and Healthcare products Regulatory Agency. Rimonabant: depression; psychiatric reactions. Drug Saf Update 2008; 5(10): 2–4Google Scholar
- 30.European Medicines Agency. Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant) [media release]. 2008 Oct 23 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500014779.pdf [Accessed 2011 Apr 19]
- 32.Office of National Statistics. Migration statistics 2008: annual report [online]. Available from URL: http://www.statistics.gov.uk/downloads/theme_population/Migration-Statistics-2008-Annual-Report.pdf [Accessed 2010 Feb 17]